There is encouraging news for people living with hormone receptor–positive, HER2 negative metastatic breast cancer. For tumors that have a specific change called a PIK3CA mutation, doctors now have targeted treatments that work directly on the cancer’s growth pathway. Two of these medicines are alpelisib (Piqray®) and inavolisib (Itovebi®). These medications are taken as pills and are used alongside hormone therapy to help slow cancer growth when hormone treatments alone are no longer effective. Because these drugs only work if a PIK3CA mutation is present, genetic testing of the cancer is an important step. Your care team can help determine whether one of these options may be right for you and how it fits into your overall treatment plan.
Explore the links below to learn about the latest biomarker recommendations, how the PIK3CA biomarker can help guide treatment decisions, and current clinical trials related to this biomarker.
- Healthline: PIK3CA Mutations in Breast Cancer: What Does It Mean?
- Breast Cancer Now: New Triplet therapy improves survival in advanced breast cancer
- Susan G. Komen: Breast Cancer Breakthroughs Episode 16: On the Horizon of PI3K Pathway Inhibition
- ASCO Daily News: Treatment Down the Line: Exploring Third-Line Options for ER-Positive,PIK3CA-Mutated Breast Cancer
- Metastatic Trial Search: MBC Trials that Target the PIK3CA Mutation
Last Modified on May 8, 2026